Barinthus Biotherapeutics (BRNS) Shares Outstanding (Diluted Average) (2022 - 2026)

Barinthus Biotherapeutics has reported Shares Outstanding (Diluted Average) for 5 years, with the latest figure at $40.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 1.45% year-over-year to $40.8 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (up 1.45% YoY), and the FY2025 full-year result was $40.5 million, up 3.0% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $40.8 million, up from $40.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $40.8 million in Q1 2026, with the low at $38.0 million in Q1 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $39.2 million across 5 years, with a median of $38.9 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) rose 0.1% — and 2025, when it increased 3.85%.
• Barinthus Biotherapeutics' Shares Outstanding (Diluted Average) stood at $38.2 million in 2022, then climbed by 0.57% to $38.4 million in 2023, then advanced by 2.51% to $39.3 million in 2024, then climbed by 3.0% to $40.5 million in 2025, then advanced by 0.79% to $40.8 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $40.8 million (Q1 2026), $40.5 million (Q4 2025), and $40.7 million (Q3 2025), per Business Quant data.